ReShape Lifesciences Secures USPTO Allowance for Advanced Diabetes Neuromodulation Technology

April 21, 2025

DENVER, Colo., Apr 21, 2025 (247marketnews.com)- ReShape Lifesciences (NASDAQ:RSLS) reported that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for patent application 18/069,689, titled “High-Frequency Low Duty Cycle Patterns for Neural Regulation.” The patent, set to protect the technology until August 4, 2037, enhances the company’s Diabetes Neuromodulation system, which builds on its proprietary vagus nerve block (vBloc) platform combined with vagus nerve stimulation to treat Type 2 diabetes, a condition often associated with obesity.

Paul F. Hickey, ReShape’s CEO and President, said, “The recent allowance of this patent—coming shortly after the Notice of Allowance received in March—further reinforces the promise of our groundbreaking Neuromodulation technology. Designed to personalize diabetes management, this innovation has demonstrated the potential to reduce reliance on medications by optimizing glucose control. In doing so, it aims to lower overall treatment costs and decrease complications associated with poor blood sugar management and medication non-compliance.

“Similar to other patent families within ReShape, the Diabetes Neuromodulation technology is backed by a strong intellectual property portfolio, consisting of 63 issued or pending patents. These patents span key areas such as vagal neuromodulation, glucose regulation, artificial intelligence, and Bluetooth-enabled applications—collectively securing a clear path to commercialization and offering robust protection against competitive threats.”

The ReShape Diabetes Neuromodulation system, previously known as Diabetes Bloc-Stim Neuromodulation (DBSN), is a minimally invasive implantable device that delivers bio-electronic neuromodulation to vagus nerve branches regulating plasma glucose. It stimulates pancreatic vagus celiac fibers to boost insulin release while blocking the hepatic vagal branch to reduce glucose release and insulin resistance. Offering equivalent efficacy with 10 times lower energy consumption than existing devices, the system is compatible with standard implantable pulse generators, enabling cost-effective development. ReShape’s reversible and adjustable electrical blockade is designed to outperform standalone vagus nerve stimulation or ligation, avoiding irreversible nerve damage and undesirable side effects.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (RSLS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.